RightFit
RecruitingNot applicable

The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer

The Impact of Surgical Technique on Circulating Tumor DNA in Early-Stage Non-Small Cell Lung Cancer

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

  • Time periods mentioned: 2 years, 5 years

Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.

Show the study's own words
  • "After completion of surgery, patients are followed up at day 1, day 7, days 7-28, 4 months, every 6 months for 2 years, then every 6 months for up to 5 years"
Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study compares two ways to cut lung blood vessels during surgery: cutting the vein first or the artery first. It tests whether cutting the vein first lowers the amount of tumor DNA in the blood. It is for adults with confirmed or suspected stage I–III non-small cell lung cancer who are scheduled for lung surgery.

This clinical trial compares the effect of pulmonary vein-first surgical technique to pulmonary artery-first surgical technique in decreasing circulating tumor cell deoxyribonucleic acid (ctDNA) in patients with stage I-III non-small cell lung cancer. Pulmonary vein first and pulmonary artery first surgical techniques are standard surgical techniques for the division of the blood vessels during lung resection surgery. Pulmonary vein-first surgical technique may reduce the risk of shedding tumor cells during surgery and influence long term overall survival.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • You are age 18 or older.
  • You have confirmed or suspected stage I–III non-small cell lung cancer.
  • You can have and are scheduled for surgery to remove a section or lobe of your lung as part of your usual care.

Who can't join

  • You had another cancer diagnosed within the past 5 years. Exceptions include cancer limited to the breast milk ducts (DCIS), cancer in the bladder’s surface layer, non-melanoma skin cancer, or another cancer that does not need treatment.
  • You had chemotherapy, immune-based cancer treatment, or radiation treatment before surgery.
  • You receive a blood transfusion around the time of surgery.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Any patients 18 years of age or older with confirmed or suspected early-stage (stage I-III) NSCLC * Eligible and scheduled for surgical anatomic lung resection (e.g. lobectomy or segmentectomy) as routine clinical care for their disease Exclusion Criteria: * Previous cancer diagnosis within 5 years (except ductal carcinoma in situ \[DCIS\] of the breast, superficial bladder cancer, non-melanoma skin primary, other malignancy that does not require treatment). * Preoperative chemotherapy, immunotherapy, or radiation therapy * Receipt of perioperative blood transfusion

Study sites (4)

PA